4-羟基-2-氯苯乙酮 | 41068-36-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-羟基-2-氯苯乙酮
• 中文别名: 2-氯-4-羟基苯乙酮
• 英文名称: 2-chloro-4-methoxyacetophenone
• 英文别名: 1-(2-chloro-4-methoxyphenyl)ethane-1-one；1-(2-chloro-4-methoxyphenyl)ethan-1-one；1-(2-chloro-4-methoxyphenyl)ethanone；2-Chlor-4-methoxyacetophenon；1-(2-chloro-4-methoxy-phenyl)-ethanone；1-(2-Chlor-4-methoxy-phenyl)-aethanon
• CAS: 41068-36-4
• 化学式: C₉H₉ClO₂
• 分子量: 184.622
• InChiKey: CPHAKIQSOMATHD-UHFFFAOYSA-N

物化性质

• 熔点：
  26–27°C
• 沸点：
  151 °C(Press: 12 Torr)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319
• 储存条件：
  室温下保存，并保持干燥和密封。

反应信息

• 作为反应物：
  描述：

  4-羟基-2-氯苯乙酮 在 aluminum (III) chloride 、 溴 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 1.5h， 生成 4-(2-chloro-4-methoxyphenyl)-1,2-bis(4-methoxyphenyl)-butane-1,4-dione
  参考文献：
  名称：

  Influence of Chlorine or Fluorine Substitution on the Estrogenic Properties of 1-Alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles

  摘要：

  In continuation of Our previous work, several 1- alkyl-2,3,5-tris(4-hydroxyphenyl)aryl-1H-pyrroles with chlor-Me or fluorine substituents in the aryl residues were synthesized and tested for estrogen receptor (ER) binding at isolated ER alpha/ER beta. receptors (HAP assay), and. in trans activation assays using ER alpha-positive MCF-7/2a as well as U2-OS/ER alpha and U2-OS/ER beta cells. In the competition experiment at ER alpha the compounds displayed very high relative binding-affinities of up to 37% (determined for 8m) but with restricted subtype selectivity (e.g., ER alpha/ER beta (8ma) = 9). The highest estrogenic potency in ER alpha-positive MCP-7/2a cells was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-prolayl-1H-pyriole 8m (EC50 = 23 nM), while in U2-OS/ER alpha cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4-hydroxyphenyl)-1H propyl-1H pyrrole 8b (EC50 = 0.12 nM) was the Most potent agonist, only 30 fold less active than estradiol (E2, EC50 = 0.004 nM). In U2-OS/ER beta cells for all pyrroles no transactivation could be observed, which indicates that they are selective ER alpha agonists in Cellular systems.

  DOI：

  10.1021/jm300860j
• 作为产物：
  描述：

  3-氯苯酚 在 sodium hydroxide 、 samarium (III) iodide 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 4-羟基-2-氯苯乙酮
  参考文献：
  名称：

  Chen, Xiaohang; Yu, Mingxin; Wang, Meijun, Journal of Chemical Research, 2005, # 2, p. 80 - 81

  摘要：

  DOI：

文献信息

• [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
  申请人：ABBOTT HEALTHCARE PRODUCTS BV

  公开号：WO2011023795A1

  公开（公告）日：2011-03-03

  The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的（硫）吗啉衍生物，其中R1从氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烯基，（6-8C）双环烷基，（8-10C）双环基团中选择，每个基团可选择地取代为（1-4C）烷基，苯基，联苯基，萘基，每个基团可选择地取代为一个或多个取代基，独立选择自卤素，（1-4C）烷基可选择地取代为一个或多个氟原子，（2-4C）炔基，（1-4C）氧烷基可选择地取代为一个或多个氟原子，氨基，二（1-4C）烷基氨基，-SO2-（1-4C）烷基，-CO-（1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环烃，每个基团可选择地取代为（1-4C）烷基，单环杂环烃可选择地取代为卤素，（1-4C）烷基或取代为苯基的苯基，可选择地取代为（1-4C）烷基，和双环杂环烃可选择地取代为（1-4C）烷基；A从-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C=C-，-CCH3-O-和连接基-Y-（CH2）n-X-中选择，其中Y连接到R1并从键，-O-，-S-，-SO-，-SO2-，-CH2-O-，-CO-，-O-CO-，-CO-O-，-CO-NH-，-NH-CO-，-C=C-和-C≡C-中选择；n是1到10的整数；X连接到苯基/吡啶基团并从键，-O-，-S-，-SO-，-SO2-，-NH，-CO-，-C=C-和-C≡C-中选择；环结构B可选择地含有一个氮原子；R2是H，（1-4C）烷基可选择地取代为一个或多个氟原子，（1-4C）氧烷基可选择地取代为一个或多个氟原子，或卤素；R3是（1-4C）烷基-R5，其中烷基基团可取代为（CH2）2形成环丙基基团或一个或两个卤素原子，或R3是（3-6C）环烷基-R5或-CO-CH2-R5，其中R5是-OH，-PO3H2，-OPO3H2，-COOH，-COO（1-4C）烷基或四唑-5-基；R4是H或（1-4C）烷基；R6是一个或多个取代基，独立选择自H，（1-4C）烷基或氧代基；W是-O-，-S-，-SO-或-SO2-；或其药学上可接受的盐，溶剂或水合物；但是，公式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉乙醇或4-[4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂或水合物。本发明的化合物具有对S1P受体的亲和力，可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• Transfer hydrogenation of ketones catalyzed by nickel complexes bearing an NHC [CNN] pincer ligand
  作者：Zijing Wang、Xiaoyan Li、Shangqing Xie、Tingting Zheng、Hongjian Sun

  DOI：10.1002/aoc.4932

  日期：2019.6

  Four NHC [CNN] pincer nickel (II) complexes, [iPrCNN (CH2)4‐Ni‐Br] (5a), [nBuCNN (CH2)4‐Ni‐Br] (5b), [iPrCNN (Me)2‐Ni‐Br] (6a) and [nBuCNN (Me)2‐Ni‐Br] (6b), bearing unsymmetrical [C (carbene)N (amino)N (amine)] ligands were synthesized by the reactions of [CNN] pincer ligand precursors 4 with Ni (DME)Cl2 in the presence of Et3N. Complexes 5a and 5b are new and were completely characterized. The transfer

  四种NHC [CNN]钳形镍（II）络合物，[ i Pr CNN（CH 2）4 -Ni-Br]（5a），[ n Bu CNN（CH 2）4 -Ni-Br]（5b），[ i Pr CNN（Me）2 -Ni-Br]（6a）和[ n Bu CNN（Me）2 -Ni-Br]（6b）带有不对称的[C（卡宾）N（氨基）N（胺）]配体在Et 3 N存在下，通过[CNN]钳型配体前体4与Ni（DME）Cl 2的反应合成。图5a和5b是新的并且已被完全表征。探索了四种钳型镍配合物催化的酮的转移加氢反应。配合物5a和6a具有比5b和6b更好的催化活性。结合NaO t Bu / i PrOH / 80°C和2％的5a催化剂负载量，可获得77-98％的芳族醇收率。
• 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS
  申请人：Hunziker Daniel

  公开号：US20100249139A1

  公开（公告）日：2010-09-30

  The present invention relates to compounds of formula I wherein R 1a to R 1e and R 2 to R 5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.

  本发明涉及以下式I的化合物 其中R 1a 至R 1e 和R 2 至R 5 如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物是糖皮质激素受体拮抗剂，可用于治疗和/或预防疾病，如糖尿病、血脂异常、肥胖、高血压、心血管疾病、肾上腺失调或抑郁症。
• A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication
  作者：Jinwoo Kim、Yu Kyoung Jung、Chonsaeng Kim、Jin Soo Shin、Els Scheers、Joo-Youn Lee、Soo Bong Han、Chong-Kyo Lee、Johan Neyts、Jae-Du Ha、Young-Sik Jung

  DOI：10.1021/acs.jmedchem.7b00175

  日期：2017.7.13

  associated with the exacerbation of asthma. The wide variety in hRV serotypes has complicated the development of rhinovirus replication inhibitors. In the current investigation, we developed a novel series of benzothiophene derivatives and their analogues (6–8) that potently inhibit the replication of both hRV-A and hRV-B strains. Compound 6g inhibited the replication of hRV-B14, A21, and A71, with respective

  人鼻病毒（hRVs）是普通感冒的主要致病菌，与哮喘的发作有关。hRV血清型的多样性使鼻病毒复制抑制剂的开发复杂化。在目前的调查，我们开发了一种新的苯并噻吩系列的衍生物和它们的类似物（的6 - 8），其有效地抑制HRV二者-A和HRV-B菌株的复制。化合物6g抑制hRV-B14，A21和A71的复制，其EC 50值分别为0.083、0.078和0.015μM 。针对hRV-B14和hRV-A16的加法研究结果以及对hRV-B14的抗性突变分析表明6g在病毒复制过程的早期阶段起作用，与病毒衣壳蛋白相互作用。一项分子对接研究表明6g的衣壳结合模式与pleconaril类似。最后，6的衍生物还显示出对脊髓灰质炎病毒3（PV3）复制的显着抑制作用，表明它们对其他肠道病毒物种的潜在抑制活性。
• Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 3. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of 2,2'-disubstituted butestrols and 6,6'-disubstituted metabutestrols
  作者：Rolf W. Hartmann、Alexander Heindl、Walter Schwarz、Helmut Schoenenberger

  DOI：10.1021/jm00373a001

  日期：1984.7

  The synthesis of symmetrically 2,2'-disubstituted butestrols [meso-2,3-bis(4-hydroxyphenyl)butanes] and of 6,6'-disubstituted metabutestrols [meso-2,3-bis(3-hydroxyphenyl)butanes] are described [2,2'-substituents: H (1), OH (2), F (3), Cl (4), Br (5), CH3 (6), and C2H5 (7); 6,6'-substituents: H (8), OH (9), Cl (10), and CH3 (11)]. Compounds 1-11 were obtained by reductive coupling of the corresponding

  对称的2,2'-二取代的丁烯脂[间位-2,3-双（4-羟苯基）丁烷]和6,6'-二取代的间丁烯酚[间位-2,3-双（3-羟苯基）丁烷]的合成描述[2,2'-取代基：H（1），OH（2），F（3），Cl（4），Br（5），CH3（6）和C2H5（7）；6,6'-取代基：H（8），OH（9），Cl（10）和CH3（11）]。通过将相应的1-苯基乙醇与TiCl3 / LiAlH4还原偶联并分离内消旋非对映异构体来获得化合物1-11。通过竞争性结合测定法，相对于[3 H]雌二醇，测定了测试化合物对小牛子宫雌激素受体的结合亲和力。除9外，所有其他化合物的雌激素相对亲和力（RBA）值都非常高，介于1.0％至29％之间。化合物3和6（RBA值：15和29），以及10和11（1.7和5.2）超过了相应的未取代化合物1和8（12和1.0）。在未成熟小鼠的子宫重量测试中，这些化合物表现出强（3、4、6和7），